{"name":"Janssen-Cilag International NV","slug":"janssen-cilag-international-nv","ticker":"","exchange":"","domain":"janssencilaginternational.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"double blind PR OROS methylphenidate","genericName":"double blind PR OROS methylphenidate","slug":"double-blind-pr-oros-methylphenidate","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_3"},{"name":"open label PR OROS methylphenidate","genericName":"open label PR OROS methylphenidate","slug":"open-label-pr-oros-methylphenidate","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"JNJ-55308942 High Dose","genericName":"JNJ-55308942 High Dose","slug":"jnj-55308942-high-dose","indication":"Other","status":"phase_1"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"OROS hydromorphone HCl","genericName":"OROS hydromorphone HCl","slug":"oros-hydromorphone-hcl","indication":"Moderate to severe chronic pain requiring continuous opioid therapy","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"darunavir (DRV, TMC114)","genericName":"darunavir (DRV, TMC114)","slug":"darunavir-drv-tmc114","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"}]}],"pipeline":[{"name":"double blind PR OROS methylphenidate","genericName":"double blind PR OROS methylphenidate","slug":"double-blind-pr-oros-methylphenidate","phase":"phase_3","mechanism":"Methylphenidate is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"JNJ-55308942 High Dose","genericName":"JNJ-55308942 High Dose","slug":"jnj-55308942-high-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OROS hydromorphone HCl","genericName":"OROS hydromorphone HCl","slug":"oros-hydromorphone-hcl","phase":"marketed","mechanism":"OROS hydromorphone HCl is an extended-release opioid agonist that binds to mu-opioid receptors in the central nervous system to provide sustained pain relief.","indications":["Moderate to severe chronic pain requiring continuous opioid therapy"],"catalyst":""},{"name":"darunavir (DRV, TMC114)","genericName":"darunavir (DRV, TMC114)","slug":"darunavir-drv-tmc114","phase":"phase_3","mechanism":"Darunavir is a protease inhibitor that blocks the protease enzyme in HIV, preventing viral replication.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of HIV-1 infection in adults and children"],"catalyst":""},{"name":"open label PR OROS methylphenidate","genericName":"open label PR OROS methylphenidate","slug":"open-label-pr-oros-methylphenidate","phase":"phase_3","mechanism":"Methylphenidate is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQSnlMUzhDQW1sbzc3VGVsUmU4WFBuLVRmN2Uza1ZybmNCX3RvT1ZZSlY4Q0xJV2xUdWNCZDBBS1BvdEVsZm0zOERsZXpheGsyd1ZPd1pKb3h2ZWk3TDdmWUkwbXBTMmdBN0RrcmxzdnV0cU8wLXV2Uk5xaWlHbUN2bnZUM1o3Zw?oc=5","date":"2025-10-20","type":"pipeline","source":"PharmaTimes","summary":"Amivantamab shows promise in head and neck cancer - PharmaTimes","headline":"Amivantamab shows promise in head and neck cancer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-06","type":"regulatory","source":"Medical Dialogues","summary":"JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate... - Medical Dialogues","headline":"JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPa2tnanRDSUt6Skd1VGFYZWNXdnRrN3ROT3hsLUtjQW1oVDI2RU4wQV9wYTNwQWRwZldJLTBMbmtoTUt5RlB0NU5xVmVuUEZFVGRqeGpmMFBYZTZhZkNWVFNCZ3ZxeDJndXV0Skd3NHFId1hqT2hmVE1KUDE2RWt2NlAyejZHd2pVVnBBeUZlSXZaZC1zZF9ub1VlS0o0YVU?oc=5","date":"2025-05-06","type":"pipeline","source":"PharmaTimes","summary":"Johnson & Johnson submits application for subcutaneous Rybrevant dosing - PharmaTimes","headline":"Johnson & Johnson submits application for subcutaneous Rybrevant dosing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-09","type":"regulatory","source":"PR Newswire","summary":"European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - P","headline":"European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxOZmFoNmY1S0VOdUFSV012XzRFV2QyY2hMOTIwNTBXRi1LOVNyRXZseGJoS0NjcnhCWWZpdFJBY2k3RG9JaHV6UGdBNnFQYXNGdm9LLTQ5TE1wTkZ1WjVlWDBwNk5rMVByXzBybUg5WTdTT2RlSDFlaTlSWVhyWlEtdnNwZWpCQnlwak85TzY3WHJhYjAzbWJKWk0tQmE3aGJaaXEzcG5yVk9wdFJSbEhOd0xMZHQ1cF83OXNta0RmeEFORDFibUR0UU9VOExSOVpLSXNHSjlKRGV0ZXhQX3hMeEF6NGFwa1VYX2EwalJKbFVlSDdZWS1VWnFLbGtWcjhvZ05STllwak9iM1p6Zk1uRGw2cy1FVkJSenRlUW9FeXFtc2NsMzZQaGF4Sk1May0wNkxINmpWTlJKQ19tMFI5bzNaU1BGeXJnTVVKUlEwTQ?oc=5","date":"2025-04-07","type":"regulatory","source":"PR Newswire","summary":"European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - PR Newswire","headline":"European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Pati","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOQ3dDREpnMkJ1YWxybXpqUk5DS3kwVVhOcW5PR0E2a0JuVHlsR0pXTWgtakZ2cTY1b00zYmVCbTdsWEl2RTU5YkxhVTJKNXFBS0o5bU9CSUQwbGd4YlZqNEFESVFtUm9iRG53OFF5MHBXVmxiVlp6V2xhUmE2NnVsVjQ5c25IY0FDaERGMVBNcUxQQ1JSVE1UWEdSdDdrM241c1I2ZS1VYXoyNDQ?oc=5","date":"2025-01-02","type":"regulatory","source":"PharmaTimes","summary":"EC approves Rybrevant with Lazcluze for advanced lung cancer - PharmaTimes","headline":"EC approves Rybrevant with Lazcluze for advanced lung cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPclE0TEl3THQyeFpNMVRWeUVQc1JIc01LVkw3OTBqNUoyR1RFZnE1Tnl1djhwNU1lMndmXzZMNkF6UlNYLS1jOWE3Z2dpem9MeEl3OFZzYWt0U1BmU0RVVFdJWWJTWHJPR2RaNXNqUm8wMWFhcjVMWGpMbDBBQW1yVk9NVWtFZ1ZnZkU4dTVrYTR2cWRPZEV1ZDhTRTFjbUNzN3hqNzRIMnpQNnM1TEVwa0xROVM5ZnpKNjdZbnBVYnRHYTBoUWhrVmhwWjlxYzJ1a3lYSHptS0VkX2dPQ2lMMEJoWnI2N0ZYNDFxd0pB?oc=5","date":"2024-05-06","type":"regulatory","source":"News-Medical","summary":"Janssen-Cilag seeks European approval for guselkumab in ulcerative colitis and Crohn’s disease treatment - News-Medical","headline":"Janssen-Cilag seeks European approval for guselkumab in ulcerative colitis and Crohn’s disease treatment - News","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNQ2lsbVgwbGdiZDBfTlRzMXhnVTNLWlJrR2ZRcGRwQ3JveDluVEF6X08wc3JRd1lobzhFR3kyREFoa1pKNGFFY3dxeFJfa1ZpZzd0MUd3cGZvQVpVY2dqMFVCVWhkcTRmR0tVaWRWNWpfbzVkVzRZdUFCd0UyWG83TjVWYTBvRFFlVFJMeUplMEtxZ3NEdFlkdXlYaHRNTlAxR3plMFdDVXh2THU4dE5NdGRZTm85SHhRak83MzhTWHJ1NWM5OUR2aXNfSFpWS1R5R3Q1QUJ1alQyeE5pa3RjRnI5SjgyVjFQWENvSjhOLWIxZ3FCbm9SWg?oc=5","date":"2024-04-19","type":"deal","source":"Pharmaceutical Executive","summary":"Essential Pharma Acquires Reminyl, a Cholinesterase Inhibitor to Treat Mild to Moderately Severe Dementia from Janssen Pharmaceutica NV - Pharmaceutical Executive","headline":"Essential Pharma Acquires Reminyl, a Cholinesterase Inhibitor to Treat Mild to Moderately Severe Dementia from Janssen P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOamswVWdRYUZ4VEtEV1VZUFFZSWw5dHFJSkxHckN6bk4zd0JMRlZLRG1ZNFNSZl9BSGk0UVRfdHJiWV9mMnhiNDBqaUNTNVptWDhDVmNGcUdRUlZydjJtMG1aQm5qV29XeWJZZkV5Tk5mV0Y2TmhMSlU5ajJFMjJ1LUJmVHpRa0hTa1JwOUtOZlAwaE9NTHc?oc=5","date":"2021-07-02","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Increased manufacturing capacity for COVID-19 Vaccine Janssen - European Medicines Agency (EMA)","headline":"Increased manufacturing capacity for COVID-19 Vaccine Janssen - European Medicines Agency (EMA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5fdzVzeGZ2eXhmX2l0UW5uTEJEdFFkN2tfaU9PT0cyeWZlbUt0RkR1MkEyU2l4R09va1hTN0dXTDNrYThHQVhzV3dNNUZ5RzN2STcwRjQwOHlKbEFVOG5FWUtrMnBjZ01sZVRLMU5YV2Frdw?oc=5","date":"2021-03-10","type":"pipeline","source":"ec.europa.eu","summary":"Fourth safe and effective vaccine against COVID-19 - ec.europa.eu","headline":"Fourth safe and effective vaccine against COVID-19","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiRkFVX3lxTE9aY2Y1a0FYVjBYd1BvQmU5c3c3a3gtbG5hTG42bVFJZV9SQjJuamNFUk5kdDcwTGtEbk9nMXYxcXNWM1VZVlE?oc=5","date":"2016-10-05","type":"pipeline","source":"Johnson & Johnson","summary":"Our company - Johnson & Johnson","headline":"Our company - Johnson & Johnson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOZ19KS1l5bjlsNGZjOUdpbGI2Z3dNMjlYVnJUSm1xQ01VVzR4VUJaT3JkRTAyOG9JdGh0anB2czRtLTRhd2l0aG0tb0pKdlpHVF9wZ1FsanluVmJUZzg3QThEeEVxcVFNeW9aRUk4Vy1DM2tUaE11Xzk2RGM3LXdCeHk0MDRibUNLMjQ3b0Z0WTNnZjJfVmtvRlpVSE11V1lWejhEVXpkUmFFLThC?oc=5","date":"2016-08-24","type":"regulatory","source":"European Pharmaceutical Review","summary":"Janssen submits application to the EMA to expand use of DARZALEX® (daratumumab) - European Pharmaceutical Review","headline":"Janssen submits application to the EMA to expand use of DARZALEX® (daratumumab)","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}